Editorial
Correspondence:
- 1.
- Gupta S, McCune WJ, Kaplan M, et al. Thrombosis and ischaemia in patients with systemic lupus erythematosus treated with celecoxib: a series of two cases. Arthritis Rheum 1999, 9(Suppl): S149.
- 2.
- Tsakonas E, Joseph L, Esdaile JM, et al. A long term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80-85.
- 3.
- Royal College of Ophthalmologists. Ocular toxicity and hydroxychloroquine: guidelines for screening. London: RCO, 1998.
- 4.
- Ordi-Ros J, Cortes F, Cucurull, Mauri M, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27: 1429-1433.
- 5.
- Petri M. Hopkins Lupus Cohort 1999 Update. Rheum Dis Clinics 2000; 26: 199-213.
- 6.
- Gourley MF, Austin III HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996; 125: 549-557.
- 7.
- Martin-Suarez I, D'Cruz D, Mansoor M, et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-487.
- 8.
- Houssiau F, Vasconcelos C, Abramovicz D, et al. The Euro-Lupus Nephritis Trial: comparison between a low dose and a high dose cyclophosphamide regimen. Ann Rheum Dis 1999 (EULAR abstracts): 116.
- 9.
- Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
- 10.
- Schroeder J, Schwab U, Zeuner R, et al. Plasmapheresis and subsequent pulse cyclophosphamide in severe SLE: preliminary results of the LPSG Trial. Arthritis Rheum 1997, 40(Suppl): S325.
- 11.
- Formiga F, Moga I, Pac M, et al. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology 1999; 38: 724-727.
Online responses are no longer available. Please refer to our instructions for authors page for more information.